作为国内工业规模领先、制造业门类最齐全的城市之一，苏州拥有纳米新材料等六大国家级先进制造业集群，集聚16万家工业企业。 开栏的话： 发展新质生产力是推动高质量发展的内在要求和重要着力点。今年是"十五五"开局之年，必须把因地制宜发展新质生产力摆在更加突出的战 略位置。即日起，新华社推出"因地制宜发展新质生产力"系列报道，深入展现各地立足自身定位、资源禀赋、产业基础，因地制宜发展新质生产 力的案例故事和经验启示，呈现中国经济向新向优发展的生动实践。 "老师傅"的手艺被量化为数据，机器人学习后"秒变"熟练工；小家电与人工智能（AI）融合成"新物种"，市场"蓝海"大门就此打开……在江 苏省苏州市，精致苏工与AI的融合正由点及面、由浅入深，不断催生新质生产力，助力这座江南水城攀高"智造之城"。 着眼转型升级 加快以"智"赋能 静卧海底的跨洋线缆，怎样能保证质量趋近"零缺陷"、耐住恶劣环境？这些问题，亨通智缆大模型有答案。 "模型依托亨通集团30余年积累下的工艺知识、专家经验与生产数据，有效解决制造环节的核心难题，不久前获得国家网信办备案。"亨通数 科产品总监董晓健说。 丝线穿梭，传承千年的精益求精，织就苏工美名。线缆绵 ...

Core Insights - The article discusses the launch of Novo Nordisk's long-acting recombinant factor VIII, Nuwiq®, in mainland China, marking a significant advancement in the treatment of Hemophilia A [3] Group 1: Product Overview - Nuwiq® is the first and only long-acting recombinant factor VIII approved in China, filling a gap in the treatment of Hemophilia A and enhancing patient accessibility to medication [3] - The product has shown a half-life extension to 19 hours, which is 1.6 times longer than standard formulations, reducing intravenous injection frequency by 50%-71% [2] - Clinical trials in China demonstrated a zero annual bleeding rate (ABR) of 0.00, with 69.4% of patients achieving zero bleeding status and a 94.8% success rate in stopping bleeding [4] Group 2: Market Impact - The inclusion of Nuwiq® in the new national medical insurance directory significantly lowers the treatment burden for patients, addressing the issue of affordability for innovative drugs [4] - Novo Nordisk aims to continue improving drug accessibility for Hemophilia patients in China, contributing to the "Healthy China 2030" initiative [4]

Core Viewpoint - Novo Nordisk has officially launched the long-acting recombinant coagulation factor VIII, Nuwiq, in mainland China, marking it as the first and only approved treatment for Hemophilia A in the country, which enhances patient accessibility to medication and introduces a new treatment phase for Hemophilia A patients in China [1][3]. Group 1: Product Launch and Market Impact - Nuwiq is now included in the new national medical insurance directory, significantly reducing the treatment burden for patients and addressing the issue of affordability for innovative drugs [4]. - The launch of Nuwiq fills a gap in long-term treatment options for Hemophilia A, which affects approximately 80%-85% of all hemophilia patients [3]. Group 2: Clinical Efficacy and Safety - Clinical trials, such as the Pathfinder105 study, demonstrated that patients receiving preventive treatment with Nuwiq had a median annualized bleeding rate (ABR) of 0.00, with 69.4% of patients experiencing zero bleeding events and a hemostatic success rate of 94.8% [3]. - Nuwiq extends the half-life of coagulation factor VIII to 19 hours, which is 1.6 times longer than standard formulations, allowing for a reduction of 50%-71% in intravenous injection frequency, thus improving treatment adherence [3]. Group 3: Future Commitment and Goals - Novo Nordisk aims to continue enhancing drug accessibility for Hemophilia patients in China and is committed to improving patient service systems to support the "Healthy China 2030" initiative [4].

Group 1 - The core viewpoint of the article highlights significant stock movements in the Hong Kong and US markets, driven by strategic partnerships, positive financial reports, and market trends [1][2][3][4][5][6][7]. Group 2 - Ocean Group (01991) saw a surge of over 13.3% after announcing a strategic partnership with CONSCIOUSNESS FOUNDATION LTD. to establish a joint venture focused on AI smart hardware, marking a significant step in its AI strategy [1]. - Gaming stocks continued to rise, with Melco International Development (00200) up 5.49% and Sands China (01928) up 3.26%, supported by a 24% year-on-year increase in Macau's gaming revenue for January [1]. - China Energy Storage (02399) increased by over 9.2% following its announcement to acquire 100% of Wuzhong Ruichu Technology for RMB 64 million [2]. - The real estate sector showed recovery, with Sunac China (01918) rising 8.2% as market confidence improved in January [3]. - Gold stocks collectively rose, with China’s gold reserves increasing to 74.19 million ounces, marking a continuous increase for 15 months [4]. - In the US market, Lexin Fintech (LX.US) rose 6.04% amid a broader market rally, with the Dow Jones reaching a historic high of 50,115.67 points [5]. - SpyGlass Pharma (SGP.US) debuted on the US market with a 65% increase, focusing on chronic eye disease treatments [6]. - Bitcoin-related stocks rebounded significantly, with Strategy (MSTR.US) up 26.11% [7].

美银证券发表报告指，信达生物2025年营收达119亿元，按年增长45%，基本符合该行预期。报告指， 在与信达生物的电话会议中，管理层重申对达成2027年销售目标具信心，因为成熟产品线包括 sintilimab(PD-1)持续展现强劲竞争力，市场份额保持韧性。高增长产品例如mazdutide(GCG/GLP-1 dual agonist)、tafolesimab(PCSK9)、teprotumumab(IGF-1R)及limertinib (EGFR TKI)，预期将在未来数年占据 显著市场份额。美银证券维持信达生物"买入"评级，目标价113.5港元。 ...

美银证券指，信达生物2025年第四季表现强劲，2025年营收达119亿元人民币，同比增长45%，基本符 合该行预期。2025年第四季营收达33亿元人民币，同比增逾60%。两项重点值得关注，包括六款产品获 列入2026年国家医保目录，预期将面临降价压力；及先前按原价销售的产品进行库存价格调整，暂时拖 累第四季增长。 智通财经APP获悉，美银证券发布研报称，维持信达生物(01801)"买入"评级，目标价113.5港元。 报告指，在与信达生物的电话会议中，管理层重申对达成2027年销售目标具信心，因为成熟产品线包括 sintilimab(PD-1)持续展现强劲竞争力，市场份额保持韧性。高增长产品例如mazdutide(GCG/GLP-1 dual agonist)、tafolesimab(PCSK9)、teprotumumab(IGF-1R)及limertinib (EGFR TKI)，预期将在未来数年占据 显著市场份额。 ...

Group 1 - The core point of the news is that Zhixiang Jintai's stock price increased by 5.22% to 29.83 CNY per share, with a trading volume of 75.98 million CNY and a turnover rate of 2.24%, resulting in a total market capitalization of 10.938 billion CNY [1] - Zhixiang Jintai Biopharmaceutical Co., Ltd. is located in Chongqing and was established on October 20, 2015, with its main business involving the research, production, and sales of antibody drugs. The revenue composition is 99.96% from drug sales and 0.04% from other sources [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under ICBC Credit Suisse, specifically ICBC Frontier Medical Stock A (001717), reduced its holdings by 2.5735 million shares, now holding 4.0865 million shares, which accounts for 3.5% of the circulating shares. The estimated floating profit today is approximately 6.048 million CNY [2] - ICBC Frontier Medical Stock A (001717) was established on February 3, 2016, with a latest scale of 7.777 billion CNY. It has experienced a loss of 0.16% this year, ranking 4741 out of 5579 in its category, while achieving a 17.91% return over the past year, ranking 3286 out of 4289 [2]

Core Viewpoint - The company has raised its revenue forecast for 2025 by 5.0% to 12.6 billion yuan, and its net profit forecast for 2026 has been increased by 274% to 6.68 billion yuan due to collaboration with Takeda, with a new net profit forecast for 2027 set at 4.14 billion yuan [1] Group 1 - The company forecasts a product revenue of approximately 11.9 billion yuan for 2025, representing a year-on-year growth of about 45%, with Q4 product revenue expected to be around 3.3 billion yuan, showing over 60% growth [2] - The company's product revenue has surpassed 10 billion yuan for the first time, driven by innovative products, with the oncology product portfolio expanding to 13 products by 2025 [3] - The company has seven products entering the national medical insurance directory for 2025, which will be implemented in 2026, indicating strong commercial momentum [4] Group 2 - The company is focusing on the continuous realization of innovative molecules like IBI363 and its internationalization process, with significant collaboration with Takeda worth 10 billion USD announced in October 2025 [5] - The company expects substantial profit growth in 2026 due to the anticipated progress in global development of IBI363 and other clinical trials [5]

Market Overview - The Hang Seng Index closed down 325 points, a weekly decline of 827 points, marking a 3.02% drop [3][4] - The index opened lower by 530 points, reaching a low of 26,295 points before stabilizing [3] - The total market turnover for the day was 247.865 billion HKD, with a net inflow of 14.859 billion HKD from northbound trading [3] Company News - **Xinda Biopharmaceuticals** entered a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, receiving an upfront payment of 350 million USD (approximately 2.73 billion HKD) [12] - **Meitu Inc.** expects adjusted net profit growth of 60% to 66% for the fiscal year ending December 2025, driven by rapid growth in its imaging and design products segment [13] - **Jiaxin International** anticipates a turnaround with a net profit of approximately 300 to 340 million HKD for the year ending last December, compared to a loss of 173 million HKD in the previous year [14] - **Color Star Technology** expects a net loss of 15 million HKD for the year ending last December, a reversal from a net profit of 132 million HKD in 2024, primarily due to a 45% decrease in revenue [15] Economic Indicators - Hong Kong's official foreign exchange reserves increased by 7.7 billion USD to 435.6 billion USD at the end of January, equivalent to over five times the currency in circulation [8] - China's foreign exchange reserves rose for the sixth consecutive month, reaching 3.399 trillion USD, with gold reserves increasing for 15 months [10]

公告称，公司2025年年度归属于母公司所有者的净利润仍出现亏损，但亏损金额与上年同期相比显著缩 窄，主要系公司持续落实"提质增效重回报"行动方案，商业化能力显著提升的同时不断加强费用管控与 资源聚焦。 报告期内，公司营业收入增长，主要系商业化药品的销售收入与上年同期相比有所增长。报告期内，公 司核心产品特瑞普利单抗注射液(商品名：拓益)于国内市场销售收入同比大幅增长。截至本公告披露 日，拓益已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目录中唯一用于肾癌、三阴性 乳腺癌和黑色素瘤治疗的抗PD-1单抗药物。 消息面上，近日，君实生物发布公告，预计2025年年度实现营业收入25亿元左右，同比增长28.32%左 右。预计2025年年度研发费用为13.53亿元，同比增长6.10%左右。预计2025年年度实现归属于母公司所 有者的净亏损为8.73亿左右，同比亏损减少31.85%左右。预计2025年年度扣除股份支付影响后实现归属 于母公司所有者的净亏损为7.99亿元左右，同比亏损减少37.62%左右。预计2025年年度实现归属于母公 司所有者扣除非经常性损益后的净亏损为9.85亿元左右，同比亏损减少23.64 ...